Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has been assigned a $103.00 target price by equities research analysts at Canaccord Genuity in a research note issued on Friday. The brokerage currently has a a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity’s target price points to a potential upside of 26.01% from the company’s current price.

Several other research analysts have also recently commented on RARE. Jefferies Group reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Sunday, July 17th. Leerink Swann reiterated a “buy” rating and set a $85.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, July 15th. Wedbush reiterated an “outperform” rating and set a $92.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, November 8th. Cowen and Company reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 9th. Finally, Zacks Investment Research cut shares of Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday. One analyst has rated the stock with a sell rating, two have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $94.23.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 81.74 on Friday. Ultragenyx Pharmaceutical has a 52-week low of $46.52 and a 52-week high of $117.12. The company’s market capitalization is $3.34 billion. The firm’s 50-day moving average price is $66.66 and its 200 day moving average price is $63.72.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($1.64) EPS for the quarter, missing the consensus estimate of ($1.53) by $0.11. During the same period in the prior year, the business posted ($1.03) EPS. On average, equities analysts forecast that Ultragenyx Pharmaceutical will post ($6.14) earnings per share for the current year.

In other Ultragenyx Pharmaceutical news, CFO Shalini Sharp sold 12,000 shares of the company’s stock in a transaction on Wednesday, October 19th. The shares were sold at an average price of $61.40, for a total transaction of $736,800.00. Following the completion of the transaction, the chief financial officer now owns 57,387 shares in the company, valued at approximately $3,523,561.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction on Friday, October 14th. The stock was sold at an average price of $63.02, for a total transaction of $1,260,400.00. Following the transaction, the chief executive officer now owns 480,632 shares of the company’s stock, valued at approximately $30,289,428.64. The disclosure for this sale can be found here. 10.10% of the stock is currently owned by corporate insiders.

Institutional investors have recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. increased its position in shares of Ultragenyx Pharmaceutical by 45.0% in the first quarter. Adage Capital Partners GP L.L.C. now owns 483,500 shares of the biopharmaceutical company’s stock worth $30,610,000 after buying an additional 150,000 shares during the last quarter. State Street Corp increased its position in shares of Ultragenyx Pharmaceutical by 30.6% in the first quarter. State Street Corp now owns 1,284,324 shares of the biopharmaceutical company’s stock worth $81,315,000 after buying an additional 300,901 shares during the last quarter. CAM Group Holding A S increased its position in shares of Ultragenyx Pharmaceutical by 52.5% in the second quarter. CAM Group Holding A S now owns 61,000 shares of the biopharmaceutical company’s stock worth $2,984,000 after buying an additional 21,000 shares during the last quarter. Princeton Alpha Management LP purchased a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth approximately $216,000. Finally, DekaBank Deutsche Girozentrale increased its position in shares of Ultragenyx Pharmaceutical by 222.5% in the second quarter. DekaBank Deutsche Girozentrale now owns 59,720 shares of the biopharmaceutical company’s stock worth $2,971,000 after buying an additional 41,200 shares during the last quarter. Institutional investors own 93.01% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.